Kym N. Lowes

Parkville, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

Correction to "Novel Scaffold Unlocks Potent Cross-Peptidase and Cross-Species Inhibitors as Promising Antimalarial Agents".

Correction to "Novel Scaffold Unlocks Potent Cross-Peptidase and Cross-Species Inhibitors as Promising Antimalarial Agents".

Journal: Journal of medicinal chemistry
Published: March 20, 2026

Novel Scaffold Unlocks Potent Cross-Peptidase and Cross-Species Inhibitors as Promising Antimalarial Agents.

Novel Scaffold Unlocks Potent Cross-Peptidase and Cross-Species Inhibitors as Promising Antimalarial Agents.

Journal: Journal of medicinal chemistry
Published: January 12, 2026

MK-7602: a potent multi-stage dual-targeting antimalarial.

MK-7602: a potent multi-stage dual-targeting antimalarial.

Journal: EBioMedicine
Published: June 23, 2025

Global analysis of cancer cell responses to USP9X inhibition.

Global analysis of cancer cell responses to USP9X inhibition.

Journal: The EMBO journal
Published: June 09, 2025

Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity.

Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity.

Journal: PLoS pathogens
Published: May 05, 2025

Differential regulation of BAX and BAK apoptotic activity revealed by small molecules.

Differential regulation of BAX and BAK apoptotic activity revealed by small molecules.

Journal: Science advances
Published: March 05, 2025

A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID.

A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID.

Journal: Nature communications
Published: December 18, 2024

Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements for function, structure, and drug escape.

Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements for function, structure, and drug escape.

Journal: Nature communications
Published: February 24, 2024

Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4.

Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4.

Journal: Journal of medicinal chemistry
Published: February 22, 2023

The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase.

The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase.

Journal: The Biochemical journal
Published: February 09, 2023

Structure-based development of potent Plasmodium falciparum M1 and M17 aminopeptidase selective and dual inhibitors via S1'-region optimisation.

Structure-based development of potent Plasmodium falciparum M1 and M17 aminopeptidase selective and dual inhibitors via S1'-region optimisation.

Journal: European journal of medicinal chemistry
Published: November 08, 2022

RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting.

RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting.

Journal: Frontiers in cellular and infection microbiology
Published: September 20, 2022
Showing 1-12 of 35

Last Updated: 09/26/2026